The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study

Metwally, Maha Ibrahim; Zeed, Nesma Adel; Hamed, Enas Mahmoud; Elshetry, Al Shaimaa Fathi; Elfwakhry, Rabab Mahmoud; Eldin, Ahmed M. Alaa; Sakr, Ahmed; Aly, Sameh Abdelaziz; Mosallam, Walid; Ziada, Yara Mohammed Ahmad Ali; Balata, Rawda; Harb, Ola A.; Basha, Mohammad Abd Alkhalik

doi:10.1007/s00330-021-07765-5

Cited by 46 publications

(41 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 161 duplicates were removed and the titles and abstracts of the 38 remaining articles were screened, 26 potential articles were obtained. Full‐text reviews were considered, and 20 studies met the inclusion criteria, 14–33 whereas the other six studies were excluded for the following reasons: original study involving VI‐RADS ( n = 2), non‐English language ( n = 1) and insufficient information provided ( n = 3). Ultimately, the 20 included studies that reported on 2725 patients with more than 2861 lesions provided the raw data of this meta‐analysis, as shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…The characteristics of the included studies were as follows: 13 out of 20 included studies were retrospective, and the seven other studies were prospective. All but one 32 study were carried out at a single center, and all studies recruited their patients consecutively. Seven studies used a combination of TURBT and reTURBT for high‐risk NMIBC as the reference standard, and the remaining 13 used a combination of TURBT and radical or PC.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Role of Vesical Imaging–Reporting and Data System in predicting muscle‐invasive bladder cancer: A diagnostic meta‐analysis

et al. 2021

View full text Add to dashboard Cite

The objective of this study is to systematically evaluate the diagnostic performance of the Vesical Imaging–Reporting and Data System for predicting muscle‐invasive bladder cancer. Embase, PubMed and Web of Science were systematically searched from 1 September 2018 to 30 July 2021 to include proper studies. We included studies that included data on Vesical Imaging–Reporting and Data System and their associated pathological findings, and we assessed their quality using the Quality Assessment of Diagnostic Accuracy Studies‐2 tool. The pooled sensitivity and specificity were calculated and plotted using hierarchical summary receiver operating characterisijutic modeling. Meta‐regression analysis was carried out to detect heterogeneity. A total of 20 studies with 2725 patients were included. When the cut‐off point was 3, the pooled sensitivity and specificity were 0.92 (0.89–0.94) and 0.85 (0.78–0.90), respectively, and 0.82 (0.75–0.88) and 0.95 (0.91–0.97), respectively, when the cut‐off point was 4. The area under the curve was 0.95 and 0.95, respectively. Heterogeneity was substantially considerable in sensitivity and specificity. All subgroup variables, including patient number, study design, magnetic resonance imaging field strength, number of radiologists, surgery pattern, diffusion‐weighted imaging, and dynamic contrast‐enhanced magnetic resonance imaging, contributed to sensitivity heterogeneity when the cut‐off point was 3 and specificity heterogeneity when the cut‐off point was 4. Multiple image acquisition plane of diffusion‐weighted imaging achieved a higher sensitivity than single image acquisition plane of diffusion‐weighted imaging in both the Vesical Imaging–Reporting and Data System 3 and 4 groups, and higher specificity in the Vesical Imaging–Reporting and Data System 4 group. Another significant source of heterogeneity was the cut‐off point. The diagnostic performance of the Vesical Imaging–Reporting and Data System for predicting muscle‐invasive bladder cancer was excellent in both cut‐off points of the Vesical Imaging–Reporting and Data System 3 and 4. Multiple image acquisition planes of diffusion‐weighted imaging should be given more attention in the Vesical Imaging–Reporting and Data System.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Role of Vesical Imaging–Reporting and Data System in predicting muscle‐invasive bladder cancer: A diagnostic meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…MpMRI can be considered as a safe tool to monitor local bladder treatment response given its high anatomical tissue layers resolution and non-invasiveness. Recently, the MRI VI-RADS standardization imaging protocols and reporting criteria have been retrospectively, prospectively, and multicentric validated for fine discrimination of NMIBC vs. MIBC in the pre-TURBT setting among several groups [6][7][8]. In the present preliminary report, we aimed to explore Fig.…”

Section: Discussionmentioning

confidence: 99%

Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report

et al. 2021

View full text Add to dashboard Cite

Purpose The Vesical Imaging-Reporting and Data System (VI-RADS) criteria are expanding, providing fine differentiation of bladder wall layers involvement. We aimed to explore the feasibility of a novel categorical scoring, the Neoadjuvant chemotherapy VI-RADS (nacVI-RADS) for radiologic assessment of response (RaR), to define the spectrum of treatment response among patients with muscle invasive bladder cancer (MIBC). Methods Ten consecutive patients diagnosed with non-metastatic MIBC were prospectively enrolled and addressed to NAC and underwent mpMRI before staging resection and after the chemotherapy cycles. The follow-up MRI assessment was performed using the nacVI-RADS algorithm for evaluation of response to therapy. NacVI-RADS categorically define complete RaR, based on prior VI-RADS score, presence of residual disease, tumor size, and infiltration of the muscularis propria. Results NacVI-RADS categories were able to match all the final radical cystectomy pathology both for complete pT0 responders and for the patients defined as partial or minimal responders, who only showed some RaR inter-scoring class downstaging. Conclusion This report is the preliminary evidence of the feasibility of nacVI-RADS criteria. These findings might lead to possible paradigmatic shifts for cancer-specific survival risk assessment and to possibly drive the therapeutic decision through active surveillance programs, bladder-sparing modalities, or to the standard of care.

show abstract

“…[27][28][29][30][31] These studies included a total number of 799 patients. Del Guidice et al 28,30 studies included a total of 380 patients, Metwally et al 31 included 331 patients; while the two other studies included 50 and 38 patients respectively. 27,29 Three studies used a VI-RADS 3 threshold.…”

Section: Vi-rads Score Performancementioning

confidence: 99%

Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications

Séguier

Puech

Kool

et al. 2021

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: The Vesical Imaging-Reporting and Data System (VI-RADS) score is a novel standardized approach to image and report bladder cancer (BC) with multiparametric MRI (mpMRI). Objectives: To describe and evaluate the performance of the VI-RADS score using mpMRI and assess its potential clinical applications and limitations. Methods: A systematic review was conducted using the MEDLINE and EMBASE electronic bibliographic databases between June 2020 and December 2020. All reports deemed relevant to describe the VI-RADS score and assess its performance and applications were retrieved. Results presentation stands as narrative, purely descriptive synthesis based on aggregate studies data. Results: A total of 20 relevant studies were retrieved: three meta-analyses, five prospective studies, and twelve retrospective studies. The retrospective studies covered 1676 patients, while the prospective studies included a total number of 468 patients. Pooled sensitivity, specificity to differentiate muscle-invasive from non-muscle-invasive bladder cancer, ranged from 74.1% to 97.3%, and 77% to 100%, respectively. The chosen VI-RADS score thresholds for this discrimination varied across studies. The interreader agreement ranged from 0.73 to 0.95. Currently, the potential clinical applications of VI-RADS consist of initial BC risk stratification, assessment of neoadjuvant therapies response, and bladder sparing approaches, although further validation is required. Conclusions: The VI-RADS score helps to discriminate muscle invasive from non-muscle invasive BC with good performance and reproducibility. A simple algorithm based on four basic questions may enhance its popularization. Further studies are required to validate the clinical applications.

show abstract

The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study

Cited by 46 publications

References 25 publications

Role of Vesical Imaging–Reporting and Data System in predicting muscle‐invasive bladder cancer: A diagnostic meta‐analysis

Role of Vesical Imaging–Reporting and Data System in predicting muscle‐invasive bladder cancer: A diagnostic meta‐analysis

Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report

Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications

Contact Info

Product

Resources

About